{"nctId":"NCT01073865","briefTitle":"Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer","startDateStruct":{"date":"2010-02-26","type":"ACTUAL"},"conditions":["Breast Cancer"],"count":222,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: ZD9393 (Zoladex) 10.8 mg"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ZD9393 (Zoladex) 3.6 mg"]}],"interventions":[{"name":"ZD9393 (Zoladex) 10.8 mg","otherNames":["Zoladex"]},{"name":"ZD9393 (Zoladex) 3.6 mg","otherNames":["Zoladex"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female ≥20 years and pre-menopausal.Pre-menopausal defined as 1) last menses within 1 year of randomisation, and 2) E2 ≥10 pg/mL and FSH ≤ 30 mIU/mL within 4 weeks of randomisation.\n* Hormone sensitivity (ER positive) of primary or secondary tumour tissue.\n* Histological/cytological confirmation of breast cancer and are candidates to receive hormonal therapy as therapy for advanced breast cancer.\n\nExclusion Criteria:\n\n* Patients who have received tamoxifen or other hormonal therapies as adjuvant therapy for breast cancer within 24 weeks before randomisation and/or who have received prior treatment with hormonal therapies for advanced breast cancer\n* Patients who have received LHRHa as adjuvant therapy for breast cancer within 48 weeks before randomisation\n* Patients who have relapsed during adjuvant hormonal therapy or within 48 weeks after completion of adjuvant hormonal therapy and/or","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"20 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Progression-free Survival (PFS) at 24 Weeks","description":"A patient is judged as progression-free survive at Week 24 if their PFS time is at least 24 weeks with no progression event prior to Week 24 (ie, overall visit response is complete response (CR), partial response (PR) or stable disease (SD) at a tumour assessment at least 24 weeks after randomization). Overall visit response is assessed according to the RECIST version 1.1. %PFS is the proportion of patients with PFS.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Responders at 24 Weeks","description":"Responders are defined as those patients with a best objective tumour response of CR or PR during the first 24 weeks of therapy. Tumour response is assessed according to the RECIST version 1.1. ORR is defined as the proportion of patients who are responders.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Oestradiol (E2) Serum Concentrations at 24 Weeks","description":"E2 serum concentrations (pg/mL) at 24 weeks","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.302","spread":"12.251"},{"groupId":"OG001","value":"24.798","spread":"28.149"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":108},"commonTop":["HOT FLUSH","NASOPHARYNGITIS","BACK PAIN","HEADACHE","NAUSEA"]}}}